avatar for Ying Huang, PhD

Ying Huang, PhD

Legend Biotech
Dr. Ying Huang was named Chief Executive Officer of Legend Biotech on November 6, 2020. He also has served as Chief Financial Officer since July 2019. He has over 9 years of experience in research and development at major multi-national pharmaceutical companies and 12 years of experience as a biotechnology analyst on Wall Street.

Prior to Legend Biotech, Dr. Huang was a Managing Director and Head of Biotech Equity Research at Bank of America Merrill Lynch, where he led a team of analysts covering more than 30 biotechnology companies including Amgen, Gilead, Celgene, Biogen and others encompassing a wide range of therapeutic areas. His knowledge and expertise have been recognized by the Institutional Investor survey as a top-ranked biotechnology analyst on Wall Street. Dr. Huang has been a biotech analyst since 2007 and previously worked at Wells Fargo (formerly Wachovia), Credit Suisse, Gleacher and Barclays before joining Bank of America Merrill Lynch. Besides providing investment research to investors, Dr. Huang and his team conducted due diligence for numerous successful initial public offerings (IPOs) and follow-on offerings in the biotechnology sector.

Before his Wall Street career, Dr. Huang was a Principal Scientist at Schering-Plough (now Merck & Co.) in the Department of Chemical Research focusing on small molecule drug discovery in the therapeutic areas of cardiovascular and central nervous system. He is the co-author of multiple patents and peer-reviewed publications. Dr. Huang received his Doctor of Philosophy in Bio-organic Chemistry from Columbia University, New York, USA. He also studied in the Special Class for the Gifted Young at the University of Science and Technology of China and Columbia Business School.
  • Timezone
  • Filter By Type
  • Executive Interview
  • Keynote
  • Networking Break
  • Panel Session
  • Virtual Happy Hour